---
title: "4552.JP (4552.JP) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/4552.JP/news.md"
symbol: "4552.JP"
name: "4552.JP"
parent: "https://longbridge.com/en/quote/4552.JP.md"
datetime: "2026-05-21T05:40:45.876Z"
locales:
  - [en](https://longbridge.com/en/quote/4552.JP/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/4552.JP/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/4552.JP/news.md)
---

# 4552.JP (4552.JP) — Related News

### [JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising Central Nervous System Uptake at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting](https://longbridge.com/en/news/286802236.md)
*2026-05-18T17:15:39.000Z*
> JCR Pharmaceuticals presented promising preclinical data on its JUST-AAV gene therapy platform at the ASGCT 29th Annual 

### [JCR Pharmaceuticals (TSE:4552) One Off Gain Driven Profit Challenges Bullish Earnings Narratives](https://longbridge.com/en/news/286547605.md)
*2026-05-15T10:24:21.000Z*
> JCR Pharmaceuticals (TSE:4552) reported FY 2026 results with Q4 revenue of ¥9,966 million and basic EPS of ¥3.56, markin

### [JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders](https://longbridge.com/en/news/274891044.md)
*2026-02-05T00:40:58.000Z*
> JCR Pharmaceuticals presented research at WORLDSymposium™ 2026, showcasing data on investigational treatments for lysoso

### [Jefferies Sticks to Their Hold Rating for JCR Pharmaceuticals Co., Ltd. (4552)](https://longbridge.com/en/news/274132712.md)
*2026-01-29T10:17:57.000Z*
> Jefferies analyst maintained a Hold rating on JCR Pharmaceuticals Co., Ltd. today and set a price target of Yen750.00.Cl